Results 1 to 10 of about 180 (117)

Expert opinion on the use of cladribine tablets in clinical practice [PDF]

Therapeutic Advances in Neurological Disorders, 2020
Background: Gaps in current product labels and a lack of detailed clinical guidelines leaves clinicians’ questions on the practical management of patients receiving cladribine tablets for the treatment of relapsing multiple sclerosis (MS) unanswered.
Per Soelberg Sørensen, Diego Centonze, Gavin Giovannoni, Xavier Montalban, Daniel Selchen, Patrick Vermersch, Heinz Wiendl, Bassem Yamout, Hashem Salloukh, Peter Rieckmann   +9 more
doaj   +7 more sources

Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice [PDF]

Therapeutic Advances in Neurological Disorders, 2021
Background: Gaps in current evidence and guidance leave clinicians with unanswered questions on the use of cladribine tablets for the treatment of multiple sclerosis (MS) in the era of the COVID-19 pandemic, in particular relating to COVID-19 vaccination.
Peter Rieckmann, Diego Centonze, Gavin Giovannoni, Le H. Hua, Celia Oreja-Guevara, Daniel Selchen, Per Soelberg Sørensen, Patrick Vermersch, Heinz Wiendl, Hashem Salloukh, Bassem Yamout   +10 more
doaj   +4 more sources

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets

Frontiers in Immunology, 2021
Cladribine tablets (CladT) preferentially reduce B and T lymphocyte levels. As aging is associated with a decline in immune function, the effect of CladT on lymphocyte levels may differ by age.
Gavin Giovannoni, Patrick Vermersch, Axel Nolting   +2 more
exaly   +3 more sources

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers

Therapeutic Advances in Neurological Disorders, 2019
Background: Cladribine tablets 3.5 mg/kg cumulative over 2 years (CT3.5) had significant clinical/imaging effects in patients with clinically isolated syndrome (CIS; ORACLE-MS) or relapsing-remitting MS (RRMS; CLARITY and CLARITY Extension).
Gavin Giovannoni, Olaf Stuve, Fernando Dangond   +2 more
exaly   +2 more sources

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021
Background Treatment-emergent adverse events (TEAEs) that occur close to treatment initiation may negatively affect overall tolerability and adherence. It is important to develop a clear understanding of potential early TEAEs after initiating treatment ...
Jiwon Oh, Bryan Walker, Gavin Giovannoni, Dominic Jack, Fernando Dangond, Axel Nolting, Julie Aldridge, Lori A Lebson, Thomas P Leist   +8 more
doaj   +1 more source

Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021
Background In the Phase 3, 96-week ORACLE-MS study, cladribine tablets 10 mg (3.5 or 5.25 mg/kg cumulative dosage over two years) significantly reduced lesions associated with multiple sclerosis versus placebo in participants following a first clinical ...
Mark S Freedman, Patricia K Coyle, Giancarlo Comi, Susan L Scarberry, Doris Damian, Yann Hyvert, Fernando Dangond, Andrew Galazka, Dominic Jack, Lori A Lebson, Thomas P Leist   +10 more
doaj   +1 more source

Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets

Journal of Central Nervous System Disease, 2021
Background Patients with multiple sclerosis (MS) receiving immunomodulatory drugs were excluded from clinical trials on COVID-19 vaccines. Therefore, data regarding the efficacy of COVID-19 vaccines to induce humoral immunity in MS patients treated with ...
Christoph Grothe, Falk Steffen, Stefan Bittner   +2 more
doaj   +1 more source

Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know

Neurology and Therapy, 2020
Immune reconstitution therapy (IRT) is an emerging management concept for multiple sclerosis, whereby a short course of treatment provides long-lasting suppression of disease activity.
Mohamed AlJumah, Mona Marwan Alkhawajah, Shireen Qureshi, Ibtisam Al-Thubaiti, Omar Ayoub, Saeed A. Bohlega, Areej Bushnag, Edward Cupler, Abdulkader Daif, Ahmed El Boghdady, Ahmed Hassan, Yaser Al Malik, Jameelah Saeedi, Fawzia Al-Shamrany, Eslam Shosha, Peter Rieckmann   +15 more
doaj   +1 more source

Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice

Неврология, нейропсихиатрия, психосоматика, 2020
Cladribine tablets are a new drug for the immune reconstitution therapy of highly active multiple sclerosis (HAMS). After discussing the characteristics of action of the drug in clinical trials, the authors give their own experience of its use in the ...
S. V. Petrov, O. V. Boyko, A. N. Boyko
doaj   +1 more source

Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice

Неврология, нейропсихиатрия, психосоматика, 2022
Objective: to evaluate the efficacy and safety of cladribine tablets as a treatment for immune reconstitution of highly active multiple sclerosis (HAMS) in general clinical practice.Patients and methods.
S. V. Petrov, O. V. Boyko, A. N. Boyko
doaj   +1 more source